Publication:
Electrochemical immunoplatform to help managing pancreatic cancer

dc.contributor.authorCampuzano, Susana
dc.contributor.authorNavarro, Pilar
dc.contributor.authorPingarrón, José M.
dc.contributor.authorPérez-Ginés, Víctor
dc.contributor.authorTorrente-Rodríguez, Rebeca M.
dc.contributor.authorPedrero, María
dc.contributor.authorMartínez-Bosch, Neus
dc.contributor.authorGarcía de Frutos, Pablo
dc.date.accessioned2023-06-22T12:43:21Z
dc.date.available2023-06-22T12:43:21Z
dc.date.issued2023
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) is the solid tumor with the worst prognosis, representing today the third cause of cancer-related deaths in developed countries and expected to be the second in 2030. Today, CA19-9 remains the only clinically used marker for management of PDAC (FDA-approved as a disease moni- toring marker). This work reports a disposable amperometric immunoplatform for the determination of CA19-9. The immunoplatform skilfully combines the advantages of magnetic microsupports (MBs) for implementation of the immunoassay and amperometric transduction on screen-printed carbon electrodes (SPCEs). The method involves the preparation of sándwich immunocomplexes enzymatically labeled with the enzyme horseradish peroxidase (HRP) on the MBs and uses a detection antibody conjugated to HRP. Once the HRP- labeled sandwich immunocomplexes-bearing MBs were trapped on the SPCE surface, the variation of the catho- dic current was measured in the presence of H2O2 and hydroquinone (HQ), which was directly proportional to the concentration of CA19-9. Under the optimized experimental conditions, the immunoplatform allowed the amperometric determination of CA19-9 standards over the 5.0 to 500 U mL−1 concentration range, with a limit of detection (LOD) value of 1.5 U mL−1 in 1 h. The method exhibits good reproducibility and selectivity and the magnetic immunoconjugates shows a good storage stability. The immunoplatform was applied to the deter- mination of CA19-9 in serum samples of a medium-sized cohort (22 individuals) of healthy subjects and patients diagnosed with PDAC. The obtained results demonstrated the immunoplatform ability to discriminateboth types of individuals within 1 h after sample dilution. The developed immunoplatform represents an improvement in terms of cost, applicability and accessibility compared to the ELISA-based techniques currently used in the clinic.
dc.description.departmentDepto. de Química Analítica
dc.description.facultyFac. de Ciencias Químicas
dc.description.refereedTRUE
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/77048
dc.identifier.doi10.1016/j.jelechem.2023.117312
dc.identifier.issn1572-6657(Print), 1873-2569 (Online)
dc.identifier.officialurlhttps://doi.org/10.1016/j.jelechem.2023.117312
dc.identifier.urihttps://hdl.handle.net/20.500.14352/73095
dc.journal.titleJournal of Electroanalytical Chemistry
dc.language.isospa
dc.page.initial117312
dc.publisherElsevier
dc.relation.projectIDPID2019-103899RB-I00
dc.relation.projectIDS2018/NMT-4349
dc.relation.projectIDPI20/00625
dc.relation.projectIDTRANSNANOAVANSENS-CM Program
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subject.cdu543
dc.subject.keywordImmunoplatform
dc.subject.keywordAmperometrym
dc.subject.keywordCA19-9
dc.subject.keywordPancreatic cancer
dc.subject.keywordSerum samples
dc.subject.ucmQuímica
dc.subject.ucmQuímica analítica (Química)
dc.subject.unesco23 Química
dc.subject.unesco2301 Química Analítica
dc.titleElectrochemical immunoplatform to help managing pancreatic cancer
dc.typejournal article
dc.volume.number935
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pagination_JEAC_117312.pdf
Size:
932.5 KB
Format:
Adobe Portable Document Format
Collections